Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q4 CY2025 results , with sales up 42.6% year on year to $19.29 ...

Lilly has also signaled that seven more Phase 3 trials for retatrutide are expected to conclude in 2026, making it a pivotal ...

Eli Lilly and Company (NYSE:LLY) is included in the list of the best performing S&P 500 stocks in the last five years. As of February 6, 2026, robust demand for the company’s obesity and diabetes ...

Eli Lilly (LLY) stock rises after Q4 2025 earnings beat and strong 2026 outlook following a drop led by an underwhelming ...

Eli Lilly and Company (NYSE:LLY) executives highlighted strong 2025 performance, continued demand for its incretin medicines, ...

Eli Lilly is predicting strong sales and profit growth in 2026, seemingly shrugging off the pricing pressure that weighed ...

Eli Lilly stock jumps 8% after Q4 earnings beat. Revenue hits $19.3B driven by Mounjaro and Zepbound sales growth.

Mounjaro and Zepbound combined for $11.7 billion in the fourth quarter, which beat analyst consensus of $10.6 billion.

Eli Lilly CEO David Ricks joins 'Squawk Box' to discuss the company's quarterly earnings results, state of the weight-loss ...

By Mrinalika Roy and Mariam Sunny Feb 4 (Reuters) - Eli Lilly forecast strong profit growth for 2026 on Wednesday on the back ...

Polen Capital Management Llc released its “Polen Focus Growth Strategy” Q4 2025 investor letter. A copy of the letter can be downloaded here. In Q4 2025, the Polen Focus Growth strategy delivered a -1 ...

Baron Funds, an investment management company, released its fourth-quarter investor letter for the “Baron Health Care Fund”.